News from Our Members
Promethera Biosciences and LifeLiver Sign Strategic Alliance to Develop Liver Disease Therapeutics in South Korea
January 9, 2017 – (Promothera) – “This alliance represents a great opportunity for Promethera to shape the global commercialization strategy for our novel cell-based therapeutics. Even more importantly, the partnership offers us a way to benefit from the positive environment for such cutting-edge therapies and regenerative medicine in Korea and to drive the development of our novel platforms in this key market,” said Dr. John Tchelingerian, CEO of Promethera Biosciences.
Abeona Therapeutics Receives Orphan Drug Designation in The European Union for ABO-101 Gene Therapy in Sanfilippo Syndrome Type B
January 19, 2017 – (Abeona) – “This designation builds on our commercial portfolio of AAV gene therapies that have received FDA and EMA orphan drug designations, which is an important validation of the scientific and clinical translation of these products for severely underserved patient populations,” stated Timothy J. Miller, Ph.D., President & CEO of Abeona Therapeutics Inc.
January 18, 2017 – (MaSTherCell) – MaSTherCell anticipates that it will complete the development of the initial CAR-T platform in 2018.
January 18, 2017 – (StemBioSys) – StemBioSys Inc. announced that it has entered into an agreement with VWR (NASDAQ: VWR) to distribute and market StemBioSys products. VWR will be the exclusive distributor for StemBioSys in both the United States and Canada.
Athersys Subsidiary and Leading Animal Health Company Enter Into Research and Option Agreement for Cell Therapy
January 18, 2017 – (Athersys) – Under the terms of the agreement, ReGenesys will receive an initial payment in exchange for an exclusive period to evaluate the cell therapy technology with an option to negotiate for a license for the development and commercialization of the technology for this area.
January 18, 2017 – (Invetech) – New suite of customized equipment is intended to enable scalable, cost-effective GMP manufacturing of Erytech’s proprietary therapeutic product candidates based on its ERYCAPS platform.
January 17, 2017 – (Cryoport) – As ProMab builds-out the new CAR-T cell-engineering segment of its business at its manufacturing facility in in China, Cryoport's depot in Singapore will support the transport of these products across China and around the world.
- About Us
- Get Involved
- About Regenerative Medicine
- ARM Events
- Committee Meetings
- Regenerative Medicine Industry Events
- Past Events
- ARM in Action
- Committees and Working Groups
- Technology Sections
- European Section
- Patient Resources & Advocacy
- Policy and Government Relations
- Science and Technology
- Regenerative Medicine Promotion Act
- ARM & Bioethics
- ARM Political Action Committee
- Regulatory & Legislative Priorities
- ARM MOUs
- Media Center